Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778369 | 1.00 | ADAMTS5 (0.41) | ADAMTS5MMP2MAPTALDH1A1GFER | |
| SCHEMBL1779615 | 0.91 | MAPT (0.48) | MAPTALDH1A1GFERMEN1KMT2A | |
| SCHEMBL1779616 | 0.91 | MAPT (0.48) | MAPTALDH1A1GFERMEN1KMT2A | |
| SCHEMBL12603491 | 0.89 | NR1H2 (0.47) | ADAMTS5MMP2MAPTALDH1A1MMP13 | |
| SCHEMBL1778567 | 0.81 | MAPT (0.48) | MAPTALDH1A1GFERMEN1KMT2A | |
| SCHEMBL1778569 | 0.81 | MAPT (0.48) | MAPTALDH1A1GFERMEN1KMT2A | |
| SCHEMBL12603492 | 0.79 | MAPT (0.50) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1780201 | 0.79 | CCR2 (0.50) | ADAMTS5MMP2PRCPMMP13 | |
| SCHEMBL1779594 | 0.79 | CCR2 (0.50) | ADAMTS5MMP2PRCPMMP13 | |
| SCHEMBL1778346 | 0.79 | CCR2 (0.50) | ADAMTS5MMP2PRCPMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | CCR2, CCR5, CCL2 | ADAMTS5 4753/4885MMP2 1545/4885MAPT 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.